600535.SS
600535.SS
CNE000001C81
TASLY PHARMACEUTICAL GROUP CO L
Loading chart...

Company Profile

Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical drugs. It also engages in medical instruments, agriculture, and chain drugstore activities. The company was formerly known as Tianjin Tasly Pharmaceutical Co., Ltd. and changed its name to Tasly Pharmaceutical Group Co., Ltd in May 2012. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.

Related stocks

600521.SS
600521.SS • China
ZHEJIANG HUAHAI PHARMACEUTICAL
17.45 CNY
3.91B USD 1Y -16.9%
600380.SS
600380.SS • China
JOINCARE PHARMACEUTICAL GROUP I
10.13 CNY
2.77B USD 1Y -19.3%
600566.SS
600566.SS • China
HUBEI JUMPCAN PHARMACEUTICAL CO
26.7 CNY
3.68B USD 1Y +8.3%
600664.SS
600664.SS • China
HARBIN PHARMACEUTICAL GROUP CO
7.39 CNY
2.78B USD 1Y +105.3%
000739.SZ
000739.SZ • China
APELOA PHARMA.
25.4 CNY
4.4B USD 1Y +55.9%
000513.SZ
000513.SZ • China
LIVZON GROUP
30.5 CNY
4.05B USD 1Y -21.4%
1513.HK
1513.HK • China
LIVZON PHARMA
22.16 HKD
2.51B USD 1Y -35.7%
603858.SS
603858.SS • China
SHANDONG BUCHANG PHARMACEUTICAL
14.81 CNY
2.34B USD 1Y -18.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
30.0% p.a.
Max Drawdown (5Y)
-43.7%
Sharpe Ratio (5Y)
-0.06
Beta Factor
0.21
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (30.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -72.5% in the extended horizon.
ende